Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $65.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 118.93% from the stock’s […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its target price decreased by research analysts at JPMorgan Chase & Co. from $55.00 to $50.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential […]
Clearstead Advisors LLC decreased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 29.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,095 shares of the biotechnology company’s stock after selling 862 shares during the period. Clearstead Advisors LLC’s […]
Clearstead Advisors LLC trimmed its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 29.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,095 shares of the biotechnology company’s stock after selling 862 shares during the quarter. Clearstead Advisors LLC’s holdings in Rocket Pharmaceuticals were worth $43,000 at the end of the most […]
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been assigned an average rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued a report on the […]